Michael Savona
-
Study finds World Trade Center responders at higher risk for blood cancer-associated mutations
A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease Read MoreMar 7, 2022
-
New therapeutic strategy for leukemia syndrome
Using primary cells from patients with chronic myelomonocytic leukemia, Vanderbilt researchers found synergistic inhibition of cell viability and proliferation, suggesting a new treatment strategy. Read MoreApr 20, 2021
-
One-two punch for cancer
A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients. Read MoreMar 5, 2020
-
Grant bolsters research on myelodysplastic syndromes
Michael Savona, MD, has received a competitive grant to develop therapies for patients with myelodysplastic syndromes. Read MoreAug 1, 2019
-
First VICC cancer patient treated with new immunotherapy
For the first time, Vanderbilt-Ingram Cancer Center (VICC) investigators have used a cancer patient’s own re-engineered immune cells to treat a form of blood cancer by stimulating the immune system. Read MoreMar 3, 2016
-
Myelodysplastic syndrome event scheduled for March 14
Vanderbilt-Ingram Cancer Center’s Michael Savona, associate professor of medicine and director of the Hematology Early Therapeutics Program, will headline a seminar on new therapies and treatment options for patients with myelodysplastic syndrome. Read MoreMar 11, 2015